Clinical trial
Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
NCT00042965 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00042965 |
|---|---|
| Title | Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer |
| Official title | A Phase II Study Of Capecitabine Plus Gemcitabine For Metastatic Renal Cell Carcinoma |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug |
| Interventions | capecitabine, gemcitabine hydrochloride |
| Enrollment | 60 |
| Start date | Oct 1, 2002 |
| Primary completion | Sep 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 14, 2016 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: